KHC
VIVS

Koesten Hirschmann & Crabtree’s VivoSim Labs VIVS Stock Holding History

Koesten Hirschmann & Crabtree’s Portfolio VIVS Stock Details VIVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$3 – 387
2025
Q2 		$3 Buy
+2
New +$4 ﹤0.01% 344

Other funds holding VIVS

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Koesten Hirschmann & Crabtree's VIVS Position: Q3 2025 in Review

Koesten Hirschmann & Crabtree sold out of VivoSim Labs (VIVS) in Q3 2025, closing a stake of 2 shares — an estimated $3 sold.

Koesten Hirschmann & Crabtree first reported a position in VIVS in Q2 2025 and held it in 1 quarter. The position peaked at $3 in Q2 2025. 29 funds tracked by Wall St. Rank hold VIVS as of Q3 2025.

  • Koesten Hirschmann & Crabtree reported no remaining VivoSim Labs position as of Q3 2025 after selling out during the quarter.
  • Koesten Hirschmann & Crabtree sold 2 VivoSim Labs shares in Q3 2025, an estimated $3.
  • Koesten Hirschmann & Crabtree first reported a position in VivoSim Labs in Q2 2025 and held it in 1 quarter.
  • Koesten Hirschmann & Crabtree's VivoSim Labs position peaked at $3 in Q2 2025.
  • 29 funds tracked by Wall St. Rank held VivoSim Labs as of Q3 2025.

Based on Koesten Hirschmann & Crabtree's 13F filing for Q3 2025, filed 5 Nov 2025.